NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company specializing in antiviral drug development, announced that a Phase II clinical trial of its NV-387 Oral Gummies for the treatment of Bundibugyo Ebolavirus and other Ebola viruses is expected to commence soon in the Democratic Republic of Congo (DRC). The company has secured regulatory approval from the local agency ACOREP and has appointed Professor Patrick Katoto as principal investigator. Preparatory activities, including staff training, are underway, and the NV-387 drug product is already available in the DRC, with first patient dosing anticipated within a few weeks, barring any outbreak-related impediments.
NV-387 is an orally administered broad-spectrum antiviral designed to mimic host-side features that viruses require for infection. NanoViricides believes that oral delivery could provide significant advantages in resource-limited outbreak settings compared to treatments that require intravenous infusions. This could be particularly impactful in the DRC, where healthcare infrastructure may be constrained and where rapid deployment of treatments is critical during Ebola outbreaks.
The trial is being conducted with Om Sai Clinical Research Private Limited serving as the contract research organization (CRO) for this study, as well as for the company’s planned Phase II trial of NV-387 Oral Gummies for the treatment of Mpox in the DRC. The appointment of a CRO with experience in the region may help streamline trial operations and ensure compliance with local regulations.
Ebola virus disease is a severe, often fatal illness in humans, with case fatality rates ranging from 25% to 90% depending on the outbreak and response. The current outbreak in the DRC involves the Bundibugyo strain, which has a lower fatality rate than the Zaire strain but still poses a significant public health threat. The availability of an oral antiviral could be a game-changer in outbreak response, as it would be easier to administer in field settings and could reduce the burden on healthcare workers who would otherwise need to manage IV lines for infused therapies.
NanoViricides’ platform technology, known as the nanoviricide class of drug candidates, is based on intellectual property and proprietary know-how from TheraCour Pharma, Inc. The company holds exclusive licenses for several antiviral indications, including Ebola and Marburg viruses. The development of NV-387 is part of a broader pipeline that includes candidates for respiratory infections, Mpox, and other viral diseases.
The potential impact of this trial extends beyond Ebola. If successful, the oral formulation could be repurposed for other viral outbreaks, especially in regions where access to healthcare is limited. The ability to deliver antiviral therapy orally could also improve patient compliance and reduce the need for hospitalization, easing the strain on fragile health systems.
However, the path to regulatory approval and widespread use remains lengthy and uncertain. As with all pharmaceutical development, there is no guarantee that NV-387 will demonstrate sufficient efficacy and safety in clinical trials. The company acknowledges these risks, noting that successful preclinical results do not ensure success in humans.
The initiation of this trial marks a significant step for NanoViricides, which has been focusing on advancing NV-387 into Phase II human trials. With regulatory approvals in place and the drug product already in the DRC, the company is poised to begin dosing patients in a matter of weeks, provided that local conditions allow. This trial could provide crucial data on the drug’s safety and effectiveness in a real-world outbreak setting, potentially offering a new tool in the fight against Ebola.
For more information about NanoViricides and its pipeline, visit the company’s website at https://www.nanoviricides.com. The full press release is available at https://ibn.fm/uWVTo.
